PROCEPT BioRobotics Corporation (PRCT)
PRCT Stock Price Chart
Explore PROCEPT BioRobotics Corporation interactive price chart. Choose custom timeframes to analyze PRCT price movements and trends.
PRCT Company Profile
Discover essential business fundamentals and corporate details for PROCEPT BioRobotics Corporation (PRCT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Devices
IPO Date
15 Sept 2021
Employees
756.00
CEO
Larry L. Wood
Description
PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majority—78 units—located in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.
PRCT Financial Timeline
Browse a chronological timeline of PROCEPT BioRobotics Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Aug 2026
EPS estimate is -$0.46, while revenue estimate is $92.64m.
Earnings released on 29 Apr 2026
EPS came in at -$0.56 falling short of the estimated -$0.55 by -1.82%, while revenue for the quarter reached $83.13m , beating expectations by +3.24%.
Earnings released on 25 Feb 2026
EPS came in at -$0.53 falling short of the estimated -$0.32 by -65.63%, while revenue for the quarter reached $76.38m , missing expectations by -18.54%.
Earnings released on 4 Nov 2025
EPS came in at -$0.38 surpassing the estimated -$0.41 by +7.32%, while revenue for the quarter reached $83.33m , missing expectations by -11.07%.
Earnings released on 6 Aug 2025
EPS came in at -$0.35 surpassing the estimated -$0.41 by +14.63%, while revenue for the quarter reached $79.18m , missing expectations by -6.12%.
Earnings released on 24 Apr 2025
EPS came in at -$0.45 surpassing the estimated -$0.49 by +8.16%, while revenue for the quarter reached $69.16m , beating expectations by +5.69%.
Earnings released on 25 Feb 2025
EPS came in at -$0.35 falling short of the estimated -$0.34 by -2.94%, while revenue for the quarter reached $68.24m , missing expectations by -10.19%.
Earnings released on 28 Oct 2024
EPS came in at -$0.40 surpassing the estimated -$0.48 by +16.67%, while revenue for the quarter reached $58.37m , missing expectations by -12.58%.
Earnings released on 1 Aug 2024
EPS came in at -$0.50 surpassing the estimated -$0.52 by +3.85%, while revenue for the quarter reached $53.35m , beating expectations by +6.37%.
Earnings released on 1 May 2024
EPS came in at -$0.51 surpassing the estimated -$0.55 by +7.27%, while revenue for the quarter reached $44.54m , beating expectations by +7.12%.
Earnings released on 27 Feb 2024
EPS came in at -$0.54 falling short of the estimated -$0.44 by -22.73%, while revenue for the quarter reached $43.58m , beating expectations by +3.62%.
Earnings released on 1 Nov 2023
EPS came in at -$0.51 surpassing the estimated -$0.53 by +3.77%, while revenue for the quarter reached $35.10m , missing expectations by -14.20%.
Earnings released on 27 Jul 2023
EPS came in at -$0.56 surpassing the estimated -$0.57 by +1.75%, while revenue for the quarter reached $33.10m , beating expectations by +0.32%.
Earnings released on 27 Apr 2023
EPS came in at -$0.63 falling short of the estimated -$0.59 by -6.78%, while revenue for the quarter reached $24.40m , beating expectations by +0.22%.
Earnings released on 28 Feb 2023
EPS came in at -$0.56 falling short of the estimated -$0.53 by -5.66%, while revenue for the quarter reached $23.78m , missing expectations by -2.35%.
Earnings released on 3 Nov 2022
EPS came in at -$0.51 falling short of the estimated -$0.47 by -8.51%, while revenue for the quarter reached $20.35m , beating expectations by +19.40%.
Earnings released on 4 Aug 2022
EPS came in at -$0.43 surpassing the estimated -$0.49 by +12.24%, while revenue for the quarter reached $16.69m , beating expectations by +15.86%.
Earnings released on 5 May 2022
EPS came in at -$0.39 surpassing the estimated -$0.47 by +17.02%, while revenue for the quarter reached $14.20m , beating expectations by +17.25%.
Earnings released on 8 Mar 2022
EPS came in at -$0.42 falling short of the estimated -$0.38 by -10.53%, while revenue for the quarter reached $10.14m , beating expectations by +13.22%.
Earnings released on 4 Nov 2021
EPS came in at -$1.22 falling short of the estimated -$0.42 by -190.48%, while revenue for the quarter reached $8.67m , beating expectations by +10.53%.
Earnings released on 16 Sept 2021
EPS came in at -$0.36 , while revenue for the quarter reached $7.19m .
PRCT Stock Performance
Access detailed PRCT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
